cilostazol Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	644	73963-72-1

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: OPC 13013 cilostazol cilostazole pletal OPC-13013	A quinoline and tetrazole derivative that acts as a phosphodiesterase type 3 inhibitor, with anti-platelet and vasodilating activity. It is used in the treatment of PERIPHERAL VASCULAR DISEASES; ISCHEMIC HEART DISEASE; and in the prevention of stroke. Molecular weight: 369.47 Formula: C20H27N5O2 CLOGP: 3.53 LIPINSKI: 0 HAC: 7 HDO: 1 TPSA: 81.93 ALOGS: -4.06 ROTB: 7 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

OPC 13013
cilostazol
cilostazole
pletal
OPC-13013

A quinoline and tetrazole derivative that acts as a phosphodiesterase type 3 inhibitor, with anti-platelet and vasodilating activity. It is used in the treatment of PERIPHERAL VASCULAR DISEASES; ISCHEMIC HEART DISEASE; and in the prevention of stroke.

Molecular weight: 369.47
Formula: C20H27N5O2
CLOGP: 3.53
LIPINSKI: 0
HAC: 7
HDO: 1
TPSA: 81.93
ALOGS: -4.06
ROTB: 7

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.20	g	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.00 mg/mL	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	7.73 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

Date	Agency	Company	Orphan
Jan. 15, 1999	FDA	OTSUKA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Anaemia	94.30	38.77	35	421	34757	2322872
Ventricular fibrillation	57.45	38.77	13	443	2188	2355441
Cardiac failure	47.07	38.77	16	440	12078	2345551
Cerebral haemorrhage	45.62	38.77	13	443	5491	2352138

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Cerebral infarction	112.48	35.32	33	791	5176	1740781
Tachycardia	90.95	35.32	35	789	12593	1733364
Atrial fibrillation	71.45	35.32	31	793	15080	1730877
Interstitial lung disease	63.06	35.32	25	799	9671	1736286
Haemorrhage subcutaneous	62.21	35.32	13	811	494	1745463
Cerebral haemorrhage	62.03	35.32	22	802	6255	1739702
Palpitations	60.27	35.32	22	802	6792	1739165
Melaena	54.28	35.32	19	805	5191	1740766
Agranulocytosis	52.97	35.32	17	807	3559	1742398
Haematochezia	51.42	35.32	18	806	4914	1741043
Gastrointestinal haemorrhage	50.66	35.32	24	800	14243	1731714
Cardiac failure	50.33	35.32	23	801	12579	1733378
Hypotension	49.08	35.32	30	794	29624	1716333
Thrombosis in device	48.94	35.32	12	812	939	1745018
Shock haemorrhagic	48.93	35.32	13	811	1403	1744554
Disseminated intravascular coagulation	48.72	35.32	16	808	3598	1742359
Gastric ulcer haemorrhage	48.36	35.32	12	812	987	1744970
Condition aggravated	47.19	35.32	26	798	21124	1724833
Hepatic function abnormal	45.10	35.32	18	806	7056	1738901
Acute kidney injury	42.17	35.32	29	795	34915	1711042
Anaemia	41.68	35.32	27	797	29430	1716527
Peripheral arterial occlusive disease	40.58	35.32	10	814	798	1745159
Pyrexia	39.08	35.32	31	793	46369	1699588
Acute myocardial infarction	38.47	35.32	17	807	8570	1737387
Drug interaction	38.00	35.32	25	799	27933	1718024

Pharmacologic Action:

Source	Code	Description
ATC	B01AC23	BLOOD AND BLOOD FORMING ORGANS ANTITHROMBOTIC AGENTS ANTITHROMBOTIC AGENTS Platelet aggregation inhibitors excl. heparin
FDA EPC	N0000175598	Phosphodiesterase 3 Inhibitor
MeSH PA	D018927	Anti-Asthmatic Agents
MeSH PA	D001993	Bronchodilator Agents
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D005343	Fibrinolytic Agents
MeSH PA	D006401	Hematologic Agents
MeSH PA	D018696	Neuroprotective Agents
MeSH PA	D018373	Peripheral Nervous System Agents
MeSH PA	D058987	Phosphodiesterase 3 Inhibitors
MeSH PA	D010726	Phosphodiesterase Inhibitors
MeSH PA	D010975	Platelet Aggregation Inhibitors
MeSH PA	D020011	Protective Agents
MeSH PA	D019141	Respiratory System Agents
CHEBI has role	CHEBI:50249	anticoagulant
CHEBI has role	CHEBI:63726	neuroprotective agent
CHEBI has role	CHEBI:35523	bronchodilator agent
CHEBI has role	CHEBI:35620	vasodilator agent
CHEBI has role	CHEBI:48676	fibrin modulating drug
CHEBI has role	CHEBI:50427	platelet aggregation inhibitor
MeSH PA	D014665	Vasodilator Agents

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Intermittent claudication	indication	63491006	DOID:3669
Chronic heart failure	contraindication	48447003
Kidney disease	contraindication	90708001	DOID:557
Disease of liver	contraindication	235856003	DOID:409

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Enzyme	Q14432	PDE3A_HUMAN	INHIBITOR	IC50	6.70	IUPHAR	CHEMBL
Cytochrome P450 2C9	Enzyme	P11712	CP2C9_HUMAN		IC50	5	DRUG MATRIX
cGMP-inhibited 3',5'-cyclic phosphodiesterase B	Enzyme	Q13370	PDE3B_HUMAN	INHIBITOR	IC50	6.42	IUPHAR

External reference:

ID	Source
D000077407	MESH_DESCRIPTOR_UI
4021153	VUID
N0000148605	NUI
C0055729	UMLSCUI
D01896	KEGG_DRUG
395239000	SNOMEDCT_US
4021153	VANDF
60734	MMSL
007339	NDDF
d04382	MMSL
7889	MMSL
21107	RXNORM
116087001	SNOMEDCT_US
CHEMBL799	ChEMBL_ID
N7Z035406B	UNII
5680	INN_ID
DB01166	DRUGBANK_ID
CHEBI:31401	CHEBI
7148	IUPHAR_LIGAND_ID
2754	PUBCHEM_CID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Cilostazol	HUMAN PRESCRIPTION DRUG LABEL	1	0054-0028	TABLET	50 mg	ORAL	ANDA	17 sections
Cilostazol	HUMAN PRESCRIPTION DRUG LABEL	1	0054-0044	TABLET	100 mg	ORAL	ANDA	17 sections
Cilostazol	HUMAN PRESCRIPTION DRUG LABEL	1	0093-2064	TABLET	100 mg	ORAL	ANDA	19 sections
Cilostazol	HUMAN PRESCRIPTION DRUG LABEL	1	0093-2065	TABLET	50 mg	ORAL	ANDA	19 sections
Cilostazol	HUMAN PRESCRIPTION DRUG LABEL	1	0185-0123	TABLET	50 mg	ORAL	ANDA	19 sections
Cilostazol	HUMAN PRESCRIPTION DRUG LABEL	1	0185-0223	TABLET	100 mg	ORAL	ANDA	19 sections
Cilostazol	HUMAN PRESCRIPTION DRUG LABEL	1	0615-7713	TABLET	100 mg	ORAL	ANDA	13 sections
Cilostazol	HUMAN PRESCRIPTION DRUG LABEL	1	0615-7716	TABLET	50 mg	ORAL	ANDA	14 sections
Cilostazol	HUMAN PRESCRIPTION DRUG LABEL	1	0615-7747	TABLET	100 mg	ORAL	ANDA	14 sections
CILOSTAZOL	HUMAN PRESCRIPTION DRUG LABEL	1	16590-285	TABLET	100 mg	ORAL	ANDA	20 sections
cilostazol	HUMAN PRESCRIPTION DRUG LABEL	1	50268-176	TABLET	50 mg	ORAL	ANDA	19 sections
cilostazol	HUMAN PRESCRIPTION DRUG LABEL	1	50268-177	TABLET	100 mg	ORAL	ANDA	19 sections
Cilostazol	HUMAN PRESCRIPTION DRUG LABEL	1	54868-5411	TABLET	100 mg	ORAL	ANDA	13 sections
cilostazol	HUMAN PRESCRIPTION DRUG LABEL	1	60505-2521	TABLET	50 mg	ORAL	ANDA	19 sections
cilostazol	HUMAN PRESCRIPTION DRUG LABEL	1	60505-2522	TABLET	100 mg	ORAL	ANDA	19 sections
Cilostazol	HUMAN PRESCRIPTION DRUG LABEL	1	68071-4125	TABLET	100 mg	ORAL	ANDA	19 sections
Cilostazol	HUMAN PRESCRIPTION DRUG LABEL	1	68151-3844	TABLET	50 mg	ORAL	ANDA	17 sections
Cilostazol	HUMAN PRESCRIPTION DRUG LABEL	1	68151-4123	TABLET	100 mg	ORAL	ANDA	17 sections
Cilostazol	HUMAN PRESCRIPTION DRUG LABEL	1	70436-050	TABLET	50 mg	ORAL	ANDA	19 sections
Cilostazol	HUMAN PRESCRIPTION DRUG LABEL	1	70436-051	TABLET	100 mg	ORAL	ANDA	19 sections
Cilostazol	HUMAN PRESCRIPTION DRUG LABEL	1	70518-2200	TABLET	100 mg	ORAL	ANDA	19 sections
Cilostazol	HUMAN PRESCRIPTION DRUG LABEL	1	70518-2208	TABLET	50 mg	ORAL	ANDA	19 sections
Cilostazol	HUMAN PRESCRIPTION DRUG LABEL	1	71610-037	TABLET	100 mg	ORAL	ANDA	20 sections